Status:
WITHDRAWN
Prevalence of Wildtype Amyloid After TAVR
Lead Sponsor:
North Florida Foundation for Research and Education
Conditions:
Amyloidosis
Eligibility:
All Genders
50-100 years
Brief Summary
Those with abnormal vital signs after TAVR need to be willing to obtain a bone scan to evaluate for wildtype amyloidosis. Positive bone scan findings will require evaluation for primary amyloidosis wi...
Detailed Description
This research is interested in determining how common wildtype amyloidosis is after transcatheter aortic valve replacement (TAVR). Amyloidosis is a condition characterized by abnormal protein which ca...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients that underwent a TAVR procedure at the Malcolm Randall VA Medical Center.
- Implant of current generation TAVR (i.e. Sapien S3, Evolut R, or Evolut Pro).
- Willingness to obtain bone scintigraphy if evidence of impaired hemodynamics after valve deployment.
- Willingness to have blood drawn
- Willingness to complete SF12 quality of life KCCQ
- Exclusion Criteria:
- -Patient that do not qualify for a TAVR procedure as normal clinical care
Exclusion
Key Trial Info
Start Date :
March 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 20 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03825406
Start Date
March 20 2019
End Date
March 20 2019
Last Update
March 22 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.